Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context

M Ntsekhe, JV Baker - Circulation, 2023 - Am Heart Assoc
Widespread use of contemporary antiretroviral therapy globally has transformed HIV
disease into a chronic illness associated with excess risk for disorders of the heart and …

[HTML][HTML] Cardiovascular disease risk estimation for transgender and gender-diverse patients: cross-sectional analysis of baseline data from the LITE Plus cohort study

TC Poteat, AJ Rich, H Jiang, AL Wirtz, A Radix… - AJPM focus, 2023 - Elsevier
Introduction Approximately 2% of the US population identifies as transgender, and
transgender people experience disproportionate rates of cardiovascular disease mortality …

Bidirectional pharmacokinetics of doravirine, tenofovir, and feminizing hormones in transgender women (IDentify): A randomized crossover trial

K Lam, WK Kraft, T Zhan, E Lam - Clinical and Translational …, 2024 - Wiley Online Library
Transgender women may have concerns of drug interactions between feminizing hormone
therapy (FHT) and antiretrovirals, leading to nonadherence. This randomized, three‐period …

Exogenous hormone therapy for adults who are transgender: considerations for the cardiovascular system

M Neuert - 2024 - repository.rcsi.com
The transgender population is a steadily increasing, heterogeneous group of individuals
whose gender identity and expression differ from their birth-assigned sex. Gender-affirming …

[PDF][PDF] Risco Cardiovascular em Pessoas Transgénero

RFM Pedrosa - 2023 - repositorio-aberto.up.pt
Introdução: O tópico da identidade de género tem sido alvo de cada vez maior atenção
social e científica, uma vez que o número de pessoas assumidamente transgénero tem …